For the year ending 2025-12-31, BMRN had $368,837K increase in cash & cash equivalents over the period. $724,956K in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total revenues | 3,221,253 | - | - | - |
| Cost of sales | 717,442 | - | - | - |
| Research and development-Research And Early Pipeline | 383,705 | - | - | - |
| Research and development-Later Stage Clinical Programs | 308,334 | - | - | - |
| Research and development-Marketed Products | 229,891 | - | - | - |
| S&m expenses | 530,156 | - | - | - |
| G&a expenses | 622,861 | - | - | - |
| Other segment expense, net | 79,963 | - | - | - |
| Net income | 348,901 | 426,859 | 167,645 | 141,561 |
| Non-cash changes in the fair value of contingent consideration | - | 0 | 0 | 1,704 |
| Depreciation and amortization | 79,557 | 96,426 | 104,386 | 101,969 |
| Non-cash interest expense | 2,622 | 3,359 | 4,188 | 4,117 |
| Accretion of discount on investments | 4,801 | 8,345 | 9,228 | -3,043 |
| Stock-based compensation | 181,409 | 201,571 | 207,099 | 196,308 |
| Gain on sale of nonfinancial assets | 0 | 10,000 | - | - |
| Impairment of assets | 125,012 | - | 38,608 | - |
| Roctavian inventory write-off | 119,208 | - | - | 0 |
| Gain on sale of nonfinancial assets, net | - | - | 0 | 108,000 |
| Deferred income taxes | 48,738 | 56,096 | -44,981 | -52,087 |
| Unrealized foreign exchange gain | -4,459 | 16,753 | -28,446 | 14,287 |
| Acquired in-process research & development expense | 220,963 | - | - | - |
| Other | 4,414 | -20,135 | 365 | 2,043 |
| Accounts receivable, net | 228,054 | 57,909 | 190,435 | 82,033 |
| Inventory | 116,929 | 63,530 | 157,058 | 68,264 |
| Other current assets | -8,891 | 3,778 | 50,335 | -7,822 |
| Other assets | 38,573 | 73,700 | 31,149 | 19,859 |
| Accounts payable and accrued liabilities | 66,136 | -32,240 | 68,853 | 59,018 |
| Impairment of assets and other non-cash adjustments | - | 19,889 | - | - |
| Other long-term liabilities | 14,869 | 14,761 | 23,585 | 6,933 |
| Net cash provided by operating activities | 827,994 | 572,841 | 159,259 | 175,902 |
| Purchases of property, plant and equipment | 103,038 | 85,424 | 96,691 | 120,959 |
| Maturities and sales of investments | 337,801 | 633,018 | 864,863 | 619,995 |
| Purchases of investments | 355,875 | 410,250 | 868,496 | 611,809 |
| Proceeds from sale of nonfinancial assets | 0 | 10,000 | 0 | 103,325 |
| Purchase of intangible assets | 7,937 | 11,994 | 10,920 | 10,581 |
| Acquisition, net of cash acquired | 285,193 | - | - | - |
| Investment in convertible note | - | - | - | 0 |
| Other | 0 | -1,141 | 0 | 0 |
| Net cash provided by (used in) investing activities | -414,242 | 136,491 | -111,244 | -20,029 |
| Proceeds from exercises of awards under equity incentive plans | 14,460 | 49,277 | 69,353 | 69,333 |
| Proceeds from convertible senior subordinated note offering, net | - | - | - | 0 |
| Taxes paid related to net share settlement of equity awards | 55,965 | 77,560 | 76,319 | 54,283 |
| Repurchase of common stock | - | - | - | 0 |
| Payments of contingent consideration | - | 0 | 9,475 | 31,095 |
| Repayments of convertible debt | 0 | 494,987 | - | 0 |
| Principal repayments of financing leases | - | - | 2,286 | 2,605 |
| Other | -889 | -3,177 | 0 | 0 |
| Net cash used in financing activities | -42,394 | -526,447 | -18,727 | -18,650 |
| Effect of exchange rate changes on cash | -2,521 | 4,830 | 1,308 | 32 |
| Net increase in cash and cash equivalents | 368,837 | 187,715 | 30,596 | 137,255 |
| Beginning of period | 942,842 | - | - | - |
| End of period | 1,311,679 | - | - | - |
BMRN
BMRN